Degron adds $40M to series A, supporting immunology plans for molecular glue platform
BioSpace
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-media
pharminent
May 14, 2026 (Last updated: May 14, 2026)
BioSpace
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-media